Dose escalation of paclitaxel with high-dose cyclophosphamide, with analysis of progenitor-cell mobilization and hematologic support of advanced ovarian cancer patients receiving rapidly sequenced high-dose carboplatin/cyclophosphamide courses Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Cyclophosphamide
  • Ovarian Neoplasms
  • Paclitaxel

abstract

  • The addition of escalating-dose Taxol to high-dose cyclophosphamide does not compromise PBP mobilization. The use of PBP mobilized in this fashion provides reliable engraftment after sequential administration of high-dose carboplatin/cyclophosphamide. Toxicities produced with this approach are manageable. The response rates demonstrated are promising and warrant further evaluation.

publication date

  • May 1995

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed ID

  • 7537799

Additional Document Info

start page

  • 1160

end page

  • 6

volume

  • 13

number

  • 5